Lidocaina-Cetrimide Spray Ogna

Lidocaine, the active ingredient in Lidocaina-Cetrimide Spray Ogna, is a local anesthetic presented as a spray for oromucosal use. Together with cetrimide, it provides rapid topical anesthesia and antiseptic protection, helping to relieve pain and prevent infection in minor oral lesions for both adults and children.

GNH USA supplies Lidocaina-Cetrimide Spray Ogna as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, dental clinics and other healthcare providers worldwide through established distribution networks and regulatory‑approved channels, ensuring timely delivery and product integrity.

Lidocaina‑Cetrimide Spray is employed for topical antisepsis and local anesthesia of the oral mucosa, addressing conditions that require pain control and infection prevention. - Oral mucosal antisepsis: reduces microbial load on the oral cavity before dental or surgical procedures. - Local anesthesia of oral mucosa: provides temporary numbness to facilitate minor interventions such as scaling or suturing. - Minor oral lesions: alleviates pain and helps prevent secondary infection in aphthous ulcers, traumatic injuries or post‑extraction sites. - Pre‑procedural oral rinse: offers rapid numbing and antiseptic action as a rinse prior to invasive oral procedures.

Lidocaina‑Cetrimide Spray may cause local or systemic reactions; reported adverse events are classified as follows.

Common Side Effects: - Mild burning sensation at the application site: brief discomfort that usually resolves within minutes. - Transient numbness lasting up to several hours: normal effect of lidocaine, subsides as the drug wears off. - Altered taste perception: temporary metallic or bitter taste that normalizes after the spray is cleared. - Local erythema or mild irritation: redness or slight swelling of the oral mucosa that disappears without treatment.

Serious or Rare Side Effects: - Allergic reactions such as angioedema or anaphylaxis: rapid swelling, hives, or respiratory difficulty requiring immediate medical attention. - Severe mucosal ulceration or necrosis: extensive tissue damage beyond normal irritation, may need professional evaluation. - Systemic lidocaine toxicity presenting with CNS symptoms (e.g., dizziness, seizures, visual disturbances): rare but serious, warrants urgent care.

When using Lidocaina‑Cetrimide Spray, certain precautions help ensure safety and effectiveness. - Allergy assessment: verify the patient has no known hypersensitivity to lidocaine or cetrimide. - Pediatric use: limit application area and monitor children closely for adverse reactions. - Avoid excessive application: prevent systemic absorption by adhering to recommended amount. - Do not apply on extensively ulcerated or necrotic mucosa: may increase irritation or infection risk. - Pregnancy and lactation: consult a healthcare professional before use, as safety data are limited. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lidocaina‑Cetrimide Spray can interact with certain systemic medications; awareness of these interactions is important.

Major Interactions (Avoid): - Concurrent use of other local anesthetics: additive toxicity may lead to systemic lidocaine overdose. - Systemic CNS depressants (e.g., barbiturates, opioids): may enhance lidocaine’s central nervous system effects. - Class I antiarrhythmic agents (e.g., quinidine, procainamide): can increase plasma lidocaine concentrations.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may potentiate lidocaine’s cardiac effects; monitor heart rate and rhythm. - Alcohol consumption: may increase systemic absorption of lidocaine; advise caution.